

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 14, 2025



Consolidated Financial Results for the six months Ended September 30, 2025 (Under IFRS)

Company name: Sawai Group Holdings Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4887
 URL: <https://www.sawaigroup.holdings>
 Representative: Mitsuo Sawai, President and Representative Director
 Inquiries: Taku Nakaoka, Group Chief Financial Officer
 Telephone: +81-6-6105-5818
 Scheduled date to file semi-annual securities report: November 14, 2025
 Scheduled date to commence dividend payments: December 1, 2025
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Scheduled (for institutional investors and analysts)

(Yen amounts are rounded to the nearest millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2025	98,843	12.5	8,534	(27.4)	7,962	(30.2)	5,846	(69.1)
September 30, 2024	87,870	0.5	11,755	7.9	11,409	6.6	18,901	124.9

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Six months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
September 30, 2025	5,846	(69.1)	6,100	(17.2)	50.63	50.46
September 30, 2024	18,901	123.8	7,372	(55.4)	146.25	145.82

Note: 1. As the Company classifies its U.S. Business as a discontinued operation in this summary, revenue, operating profit and profit before tax include the amount only from the Company's continued operation while profit for the period and profit attributable to owners of the Parent include the amount from the Company's continued and discontinued operation.
 2. The Company conducted a 3-for-1 stock split for shares of its common stock, with an effective date of October 1, 2024. The basic and diluted earnings per share are calculated assuming that the share split was implemented at the beginning of the fiscal year ended March 31, 2025.

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2025	355,776	176,856	176,856	49.7
March 31, 2025	354,623	173,854	173,854	49.0

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	78.00	—	27.00	—
Fiscal year ending March 31, 2026	—	27.00			
Fiscal year ending March 31, 2026 (Forecast)			—	28.00	55.00

Note: 1. Revisions to the forecast of cash dividends most recently announced: None

2. The Company conducted a 3-for-1 stock split for shares of its common stock, with an effective date of October 1, 2024. The indicated interim dividend per share for the fiscal year ended March 31, 2025 is based on the number of shares before the share split. Total cash dividends for the fiscal year ending March 31, 2025 are not presented as the amounts cannot be simply combined due to the stock split. When the stock split is not factored in, the year-end dividend will be 159 yen while the annual dividend will be 53 yen.

3. Forecast of consolidated financial results for fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Equity attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2026	202,500	7.1	20,900	416.1	19,800	526.3	14,000	17.0	121.25

Note: 1. Revisions to the forecast most recently announced: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: FrontAct Co., Ltd.

Excluded: None

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2025	115,487,137 shares
As of March 31, 2025	131,469,417 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2025	1,503 shares
As of March 31, 2025	16,018,103 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2025	115,457,314 shares
Six months ended September 30, 2024	129,237,338 shares

Note: The Company conducted a 3-for-1 stock split for shares of its common stock, with an effective date of October 1, 2024. Number of issued and outstanding (including treasury stock) at the end of period, number of treasury stock at the end of the period, and average number of shares outstanding in the period have been calculated assuming that the stock split took place at the beginning of the previous fiscal year.

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

The interim earnings conference for institutional investors and analysts is scheduled for November 18, 2025. Presentation and related materials of the conference will be promptly posted on our website.

Attachment Index

1. Financial Highlights for the six months ended September 30, 2025	2
(1) Operating Results.....	2
(2) Financial Position	5
(3) Cash Flow	6
(4) Forecast of Consolidated Financial Results and Other Forward-looking Statements	6
2. Condensed Interim Consolidated Financial Statements and Selected Notes	7
(1) Condensed Interim Consolidated Statements of Income and Condensed Interim Consolidated Statements of Comprehensive Income.....	7
(2) Condensed Interim Consolidated Statements of Financial Position	9
(3) Condensed Interim Consolidated Statements of Changes in Equity.....	11
(4) Condensed Interim Consolidated Statements of Cash Flows	12
(5) Selected Notes to Condensed Interim Consolidated Financial Statements.....	13
(Significant Uncertainty Regarding Going Concern Assumption)	13
(Discontinued Operation)	13
(Segment Information)	14
(Events after Reporting Period).....	15

1. Financial Highlights for the six months ended September 30, 2025

(1) Operating Results

Sawai Group Holdings Co., Ltd. (the “Company”) and subsidiaries (collectively, “Sawai”) have adopted International Financial Reporting Standards (IFRS) in order to increase the international comparability of its financial information within the capital market. The Company has classified its U.S. Business as a discontinued operation since the third quarter of FY2023, and the Company lost control of Sawai America Holdings Inc. (SAH), a holding company of Sawai’s U.S. Business, after transferring all shares it had held in that U.S.-based subsidiary, as well as its interests in Sawai America LLC (SAL) and interests in Upsher-Smith Laboratories, LLC (USL) on April 2, 2024. Therefore, in this summary, revenue, operating profit and profit before tax include the amount only from the Company’s continued operation, while the amounts of profit for the period and profit attributable to owners of parent total those of both the continued and discontinued operations.

During the six months ended September 30, 2025, revenue increased to JPY 98,843 million (by 12.5%), operating profit decreased to JPY 8,534 million (by 27.4%), profit before tax decreased to JPY 7,962 million (by 30.2%), and profit attributable to owners of parent decreased to JPY 5,846 million (by 69.1%) compared to the six months ended September 30, 2024.

(Millions of yen, except percentages)				
	Six months ended September 30, 2024	Six months ended September 30, 2025	Change	Change (%)
Revenue	87,870	98,843	10,973	12.5
Operating profit	11,755	8,534	(3,221)	(27.4)
Profit before tax	11,409	7,962	(3,447)	(30.2)
Profit attributable to owners of parent	18,901	5,846	(13,055)	(69.1)

Under a holding company structure, in May 2021, Sawai Group has formulated and announced the three-year medium-term management plan, “Beyond 2027,” (hereinafter, the “Medium-term Plan”), and drew up a vision for the future that we would like to aim for by fiscal year 2030, “Sawai Group Vision 2030”. Sawai Group Vision 2030 defines the world Sawai wants to build by 2030 as “A world where more people receive healthcare services and live a full life with peace of mind among society” and the ideal state it hopes to reach by 2030 as “A company with a strong presence that continues to contribute to people’s health by providing a multifaceted mix of products and services based on scientific evidence that meets individual needs.” Envisioning that Sawai will further grow, building on “Establishing a trusted corporate foundation,” the Medium-term Plan indicates the key business strategy themes of (1) Achieving steady growth in the generics market, (2) Establishing sustainability of the generics business, and (3) Continuing investment in growth areas and key management base themes of (1) Creating talent that underpins sustainable growth, (2) Working on sustainability initiatives, and (3) Improving capital efficiency.

The “Basic Policy on Economic and Fiscal Management and Reform 2021,” approved by the Japanese Cabinet in June 2021, states, “With the aim of ensuring the reliability of the quality and stable supply of generic drugs as the main pillar, the Government and the private sector will work together to strengthen the manufacturing control system, strengthen the supervision of manufacturing sites, and implement quality inspections of commercial products. The goal is to increase the volume share of generic drugs to 80% or more in all prefectures by the end of FY2023.” On the occasion of the April 2022 medical fee revision, the evaluation standards were revised in favor of pharmacies dispensing a high percentage of generic drugs and medical institutions using a high percentage of generic drugs in order to further encourage the use of generic pharmaceuticals. As a result, according to a flash report on the Japanese government’s National Health Insurance (NHI) drug price survey in September 2024, the latest volume-based share of generic drugs was 85.0%. Furthermore, in September 2024, the Medical Insurance Subcommittee of the Social Security Council of the Japanese Ministry of Health, Labour and Welfare (MHLW) revised the Roadmap for Promoting Further Use of Generic Drugs and set the following numerical targets to be met by the end of fiscal 2029: main target – achieving an 80% or more share of generic pharmaceuticals on a volume basis in all Japanese prefectures while basically maintaining a stable supply of pharmaceuticals (continuing from the former Roadmap); the secondary target (1) – increasing the percentage of ingredients (on

the basis of the number of their kinds) in which biosimilars account for 80% or more of the total number of ingredients to 60% or more; and secondary target (2) – increasing the share of generic pharmaceuticals among all pharmaceuticals on a monetary basis to 65% or more. (The Japanese government’s September 2024 NHI drug price survey showed that the share of generic pharmaceuticals among all pharmaceuticals was 62.1% on a monetary basis.) Also, since October 2024, a system for patient-selected additional medical services has been adopted so that additional financial burdens are imposed on patients who use long-listed drugs to which generic alternatives are available, leading to the likelihood of a further accelerating shift to generic drugs.

Under such circumstances, the entire Japanese drug market has faced the uncertainty of product supply due to health problems caused by pharmaceutical products of a second-tier generic drug company at the end of 2020 and violations committed by a number of generic drug companies, including major ones, against the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. In response to this situation, the Expert Panel on Comprehensive Measures to Achieve Rapid and Stable Supply of Pharmaceuticals, which MHLW convened in August 2022, discussed a wide range of subjects, including the distribution of pharmaceuticals, the National Health Insurance (NHI) drug pricing system, and structural problems faced by the Japanese generic pharmaceutical industry. In May 2024, the Study Group on Ideal Industrial Structure for a Stable Supply of Generic Drugs compiled a report. In June, the Japanese Cabinet approved the government’s Basic Policies for Economic and Fiscal Management and Reform 2024, which clearly states: “We will work to allay the current concern about the supply of pharmaceuticals, and with a stable supply of pharmaceuticals as a fundamental requirement, we will also promote the generic pharmaceutical industry’s structural reforms, which may involve its reorganization, with an eye to achieving the ideal state of the industry, while developing a legal framework for a stable supply.” To achieve this, in FY2025, NHI drug price revisions and upward revisions to the minimum drug prices have made within the scope defined according to the characteristics of each type of drug, from the perspectives of both reducing the burden on the public and thoroughly meeting demand for promoting innovation in drug discovery and for ensuring a stable supply of pharmaceuticals. Furthermore, Basic Policy on Economic and Fiscal Management and Reform 2025 also includes specific measures to ensure a stable supply of generic drugs, including promoting the reorganization of the generic drug industry to eliminate its inefficient small-volume mixed-lot production structure. In this context, the government is implementing support programs for businesses that strive to improve productivity and break away from inefficient production systems. It is also working to establish a legal framework for securing a stable generic-drug supply.

In this business environment, Sawai, as a leading generic drug manufacturer in Japan, works according to its Medium-term Plan to achieve steady growth and establish the sustainability of the generics business while establishing a trusted corporate foundation with the aim of making a valuable contribution to society in a sustainable manner as social infrastructure.

Given that the Japanese generic drug industry has seen serious quality control violations committed by certain companies, Sawai Pharmaceutical Co., Ltd. (“Sawai Pharmaceutical”), the core company in the Sawai Group, has focused on several issues such as ensuring the good quality of active pharmaceutical ingredients (APIs) in compliance with Good Manufacturing Practice (GMP) standards, maintaining the effectiveness of the quality control system through constant checks on GMP compliance at manufacturing facilities, and exerting manufacturing and quality control based on the internationally accepted Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP Guide. (The PIC/S is a non-binding, informal cooperative arrangement between Regulatory Authorities in the field of GMP of medicinal products for human or veterinary use.) Furthermore, Sawai has implemented various initiatives to ensure that medical professionals are able to use its products without concern, including disclosing the names of all its manufacturing subcontractors and API suppliers and the dates of audits performed over their operations since FY2021. Sawai also released a video introducing its efforts to improve quality control.

However, Sawai Pharmaceutical revealed that Teprenone Capsules 50 mg “Sawai” manufactured at its Kyushu Plant was inappropriately tested in the dissolution test for stability monitoring for a long time. In addition, in December 2023, Sawai received an administrative penalty from MHLW, Osaka Prefecture and Fukuoka Prefecture, for a violation against the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. The continued inappropriate testing is primarily attributed to human and structural factors. The human factors include (1) a prevalent disregard for stability monitoring; (2) an inclination to unquestioningly follow superiors’ instructions; (3) a lack of understanding of GMP among those conducting the tests. The structural factors include (1) an inadequate supervisory system for quality control and assurance; (2) insufficient management of test records; and (3) overwork and understaffing in the quality control department responsible for overseeing these

processes. We have developed the following measures aimed at preventing any recurrence and are dedicated to rebuilding trust; (1) commence a corporate culture reform project under the direct leadership of the president, (2) re-evaluate existing market products in terms of manufacturing and quality and implement corrective measures and (3) implement recurrence prevention measures in the production division including reintroduction of GMP education for all employees, clarification of the roles and responsibilities of managers and supervisors and recruitment both internally and externally for the quality control and quality assurance divisions within the plant. We are devoting Group-wide efforts to implementing these measures. In December 2024, we established the Kobe Analytical Research Center, which specializes in analytical research on carcinogenic nitrosamine drug substance-related impurities (NDSRIs). From among NDSRIs that can be contained in a minute amount in drugs, the center will focus on those for which testing methods are difficult to develop and those that are high priorities in terms of the need for analysis, and it will develop testing methods for them and use the methods to test them. The center also plans to transfer those testing methods to outside analysis contractors and internal analysis departments.

We are also pursuing even higher efficiency and lower cost for our production and supply systems by utilizing the unique characteristics of each of six factories of Sawai Pharmaceutical throughout Japan with the aim of eliminating the uncertainty of generic drug supply by accommodating growing demand, as well as addressing soaring energy and raw material prices. As part of such efforts, in September 2022, we completed the construction of an injection production facility at the Kyushu Factory site. In July 2024, we also completed the construction of a new solid formulation building, with a maximum production capacity of 3.5 billion tablets, on the premises of the Daini Kyushu Factory site. Additionally, Trust Pharmatech Co., Ltd. (“Trust Pharmatech”), a Sawai Group company established by taking over assets related to production activities from Kobayashi Kako Co., Ltd., including the staff of the relevant departments, has begun the contract manufacturing of products of Sawai Pharmaceutical, working to improve its operating rate. This new company is planning to make a capital investment in Seima Plants No. 2 and No. 3 in order to expand its overall annual production capacity by 2.5 billion tablets. We will therefore continue to work on building a solid production system with a view to enabling our group to manufacture 25 billion or more tablets a year as soon as possible. Moreover, Sawai opened and began to operate the East Japan Daini Distribution Center and the West Japan Daini Distribution Center in FY2021 with the aim of further strengthening its product supply system from the aspect of distribution. In addition, in June 2024, Sawai Pharmaceutical disclosed information on its initiatives to maintain a stable product supply in accordance with MHLW’s Guidelines for Disclosures Related to the Stable Supply of Generic Drugs. Furthermore, in September 2025, Sawai Pharmaceutical reached an agreement with Nichi-Iko Pharmaceutical Co., Ltd. to collaborate mainly in integrating both companies’ lineup of generic products. We are therefore committed to establishing a system for a stable product supply throughout the industry.

In terms of marketing, as a countermeasure against the steep rise in costs, we have passed on the cost increases to the prices of some of the products we sell to wholesale distributors, mainly low-priced ones, while working to further improve production efficiency. In addition, in March 2025, Sawai Pharmaceutical concluded an agreement with Eisai Co., Ltd. to take over Eisai’s rights to approval for manufacturing and marketing Warfarin, an oral anticoagulant, in the Japanese market. By expanding our product lineup in the cardiovascular field, we are strengthening our business foundation in that field.

In the field of product development, Sawai Pharmaceutical has selected six (6) technologies in five (5) categories from technologies that can add value to medicines and create harmony in their formulation, such as technologies for making medicines more comfortable to take and for increasing the efficiency of pharmaceutical production. These original formulation technologies are collectively named “SAWAI HARMOTECH[®]” and have been publicly disclosed.

As a new initiative for the personal health record (PHR) business, since 2022, we have been collaborating with a variety of organizations, including universities, local governments, companies, and medical institutions, to promote the utilization of PHRs. We will leverage the specialist human resources and know-how of FrontAct Co., Ltd. (“FrontAct”), a wholly owned subsidiary of ours acquired from Sumitomo Pharma Co., Ltd. in June 2025, to expand our product lineup and strengthen and grow our business foundation in the digital healthcare business, thereby changing people’s lifestyles and health in a better direction through the utilization of digital technology. We will therefore continue to utilize digital technology to further enhance people’s lifestyles and well-being. Furthermore, we concluded a licensing agreement with CureApp, Inc. to gain the right to develop and sell digital therapeutics (DTx) in the field of non-alcoholic steatohepatitis (NASH) in August 2022. In August 2024, we also concluded a sales licensing contract with CureApp for an alcoholism treatment DTx app and commenced sales in September 2025. With the aim of utilizing apps in this field to not only enhance digital-healthcare technology and expertise but also deliver IT-based solutions

directly to patients and healthcare professionals. In the medical device business, we focus on Relivion[®], a non-invasive neuromodulation device, for which we obtained manufacturing and marketing approval for use in the acute-stage treatment of migraine from the MHLW in December 2023.

As a result, the Sawai Group achieved net sales of JPY 98,843 million (an increase of 12.5% year on year) and an operating profit of JPY 8,534 million (a decrease of 27.4% year on year).

(2) Financial Position

Assets

As of September 30, 2025, current assets amounted to JPY 198,756 million, a decrease of JPY 2,067 million from March 31, 2025. The decrease was mainly due to an increase of JPY 5,490 million in inventories caused mainly by production expanded to increase our capacity for a stable supply, while a decrease of JPY 5,418 million in cash and cash equivalents as described in the cash flow. Non-current assets as of September 30, 2025 amounted to JPY 157,020 million, an increase of JPY 3,220 million from March 31, 2025. The increase was mainly due to an increase of JPY 918 million in property, plant and equipment resulting from the construction of a new solid formulation building at Sawai Pharmaceutical's Daini Kyushu Factory, and an increase of JPY 1,910 million in intangible assets mainly due to the acquisition and amortization of the rights to Warfarin, an oral anticoagulant.

Total assets as of September 30, 2025 were JPY 355,776 million, an increase of JPY 1,153 million compared to the balance as of March 31, 2025.

Liabilities

As of September 30, 2025, current liabilities amounted to JPY 102,706 million, a decrease of JPY 109 million from March 31, 2025. The decrease was mainly due to an increase of JPY 16,325 million in short-term borrowings in accordance with funding plans, while a decrease JPY 6,926 million in trade and other payables, a decrease JPY 12,799 million in provisions. Non-current liabilities as of September 30, 2025 was JPY 76,213 million, a decrease of JPY 1,741 million from March 31, 2025, primarily due to a decrease of JPY 2,162 million in bonds and borrowings resulting from repayments of long-term borrowings.

Total liabilities as of September 30, 2025 were JPY 178,919 million, a decrease of JPY 1,850 million compared to the balance as of March 31, 2025.

Equity

Total equity as of September 30, 2025 was JPY 176,856 million, an increase of JPY 3,002 million compared to the balance as of March 31, 2025, primarily due to the net profit for the period ended September 30, 2025, the payment of dividends of surplus. As a result, the ratio of equity attributable to owners of parent to total assets as of September 30, 2025 became 49.7% (up from 49.0% as of March 31, 2025).

(3) Cash Flow

Cash and cash equivalents as of September 30, 2025 decreased by JPY 5,418 million to JPY 33,367 million, compared to the balance as of March 31, 2025.

The results of cash flow for each activity, including the cash flow of the discontinued operation, are as follows:

Cash flows used in operating activities was JPY 1,828 million for the current period (generation of JPY 7,000 million in the same period of the previous year) which mainly consists of profit before tax (JPY 7,962 million), depreciation and amortization (JPY 7,768 million), increase in inventories (JPY 5,311 million), and decrease in provisions (JPY 12,799 million).

Cash flows used in investing activities was JPY 13,771 million for the current period (generation of JPY 14,910 million in the same period of the previous year) which mainly consists of the acquisition of property, plant and equipment (JPY 7,734 million) and the acquisition of intangible assets (JPY 7,244 million).

Cash flows generated from financing activities was JPY 10,155 million for the current period (usage of JPY 9,305 million in the same period of the previous year) which mainly consists of an increase of short-term borrowings (JPY 16,325 million), payments of dividend (JPY 3,117 million) , and repayments of long-term borrowings (JPY 2,173 million).

(4) Forecast of Consolidated Financial Results and Other Forward-looking Statements

Regarding the forecasts of consolidated financial results for the fiscal year ending March 31, 2026, as announced on November 10, 2025, we expect revenue of JPY 202,500 million, operating profit of JPY 20,900 million, profit before tax of JPY 19,800 million, and profit attributable to owners of parent of JPY 14,000 million.

In terms of the forecasts of consolidated financial results for the fiscal year ending March 31, 2026, as follows.

	Revenue	Operating profit	Profit before tax	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Fiscal year ending March 31, 2026	202,500	20,900	19,800	14,000	121.25

2. Condensed Interim Consolidated Financial Statements and Selected Notes

(1) Condensed Interim Consolidated Statements of Income and Condensed Interim Consolidated Statements of Comprehensive Income

(Condensed Interim Consolidated Statements of Income)

	Millions of yen (except per share data)	
	Six months ended September 30, 2024	Six months ended September 30, 2025
Continued Operations		
Revenue	87,870	98,843
Cost of sales	(60,544)	(69,083)
Gross profit	27,326	29,761
Selling, general and administrative expenses	(10,858)	(11,975)
Research and development expenses	(5,373)	(5,244)
Other income	776	66
Other expenses	(117)	(4,073)
Operating profit	11,755	8,534
Finance income	118	76
Finance expenses	(463)	(648)
Profit before tax	11,409	7,962
Income tax expenses	(3,538)	(1,954)
Profit for the period from continued operations	7,871	6,007
Discontinued Operation		
Profit (loss) for the period from the discontinued operation	11,029	(162)
Profit for the period	18,901	5,846
Profit attributable to:		
Owners of parent	18,901	5,846
Earnings per share (Yen)		
Basic earnings per share		
Continued operations	60.91	52.03
Discontinued operation	85.34	(1.40)
Basic earnings per share	146.25	50.63
Diluted earnings per share		
Continued operations	60.73	51.86
Discontinued operation	85.09	(1.40)
Diluted earnings per share	145.82	50.46

(Condensed Interim Consolidated Statements of Comprehensive Income)

Millions of yen

	Six months ended September 30, 2024	Six months ended September 30, 2025
Profit for the period	18,901	5,846
Other comprehensive income		
Items that will not be reclassified to profit or loss:		
Changes in fair value of financial assets measured at fair value through other comprehensive income	142	255
Items that may be reclassified to profit or loss:		
Exchange differences on translation of foreign operations	(11,670)	(0)
Other comprehensive income for the period, net of tax	(11,529)	255
Total comprehensive income for the period	7,372	6,100
Total comprehensive income attributable to:		
Owners of parent	7,372	6,100

(2) Condensed Interim Consolidated Statements of Financial Position

Millions of yen

	As of March 31, 2025	As of September 30, 2025
Assets		
Current assets		
Cash and cash equivalents	38,785	33,367
Trade and other receivables	48,879	48,103
Inventories	109,867	115,357
Other financial assets	2,480	372
Other current assets	812	1,557
Total current assets	200,823	198,756
Non-current assets		
Property, plant and equipment	111,876	112,794
Intangible assets	27,196	29,106
Other financial assets	4,134	4,382
Other non-current assets	463	469
Deferred tax assets	10,132	10,269
Total non-current assets	153,800	157,020
Total assets	354,623	355,776

Millions of yen

	As of March 31, 2025	As of September 30, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	50,777	43,851
Borrowings	21,503	37,828
Income taxes payable	1,858	2,871
Refund liabilities	1,109	1,746
Provisions	16,992	4,192
Other financial liabilities	5,237	5,768
Other current liabilities	5,339	6,450
Total current liabilities	102,815	102,706
Non-current liabilities		
Bonds and borrowings	69,836	67,675
Provisions	92	107
Other financial liabilities	7,456	7,821
Other non-current liabilities	432	474
Deferred tax liabilities	137	137
Total non-current liabilities	77,954	76,213
Total liabilities	180,769	178,919
Equity		
Share capital	10,053	10,079
Capital surplus	37,767	4,535
Retained earnings	157,257	160,047
Treasury shares	(33,243)	(3)
Other component of equity	2,020	2,198
Equity attributable to owners of parent	173,854	176,856
Total equity	173,854	176,856
Total liabilities and equity	354,623	355,776

(3) Condensed Interim Consolidated statements of Changes in Equity

Six months ended September 30, 2024

	Millions of yen							
	Equity attributable to owners of parent						Non-controlling interests	Total equity
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other component of equity	Total		
Balance at April 1, 2024	10,020	37,734	149,645	(2)	15,264	212,662	5,369	218,030
Profit for the period			18,901			18,901		18,901
Other comprehensive income					(11,529)	(11,529)		(11,529)
Total comprehensive income	—	—	18,901	—	(11,529)	7,372	—	7,372
Issuance of new shares	33	33			(66)	0		0
Acquisition of treasury shares				(16,073)		(16,073)		(16,073)
Dividends			(2,847)			(2,847)		(2,847)
Changes due to loss of control over consolidated subsidiaries						—	(5,369)	(5,369)
Transfer to retained earnings from capital surplus			1,713		(1,713)	—		—
Share based payment					96	96		96
Total transactions with owners	33	33	(1,134)	(16,073)	(1,683)	(18,824)	(5,369)	(24,192)
Balance at September 30, 2024	10,053	37,767	167,411	(16,075)	2,053	201,210	—	201,210

Six months ended September 30, 2025

	Millions of yen							
	Equity attributable to owners of parent						Non-controlling interests	Total equity
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other component of equity	Total		
Balance at April 1, 2025	10,053	37,767	157,257	(33,243)	2,020	173,854	—	173,854
Profit for the period			5,846			5,846		5,846
Other comprehensive income					255	255		255
Total comprehensive income	—	—	5,846	—	255	6,100	—	6,100
Issuance of new shares	8	8			(15)	0		0
Retirement of treasury shares		(33,240)		33,240		—		—
Dividends			(3,117)			(3,117)		(3,117)
Transfer to retained earnings from capital surplus			62		(62)	—		—
Share based payment	18	1				19		19
Total transactions with owners	26	(33,232)	(3,056)	33,240	(77)	(3,098)	—	(3,098)
Balance at September 30, 2025	10,079	4,535	160,047	(3)	2,198	176,856	—	176,856

(4) Condensed Interim Consolidated Statements of Cash Flows

	Millions of yen	
	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from operating activities		
Profit before tax	11,409	7,962
Profit (loss) before tax from the discontinued operation	14,622	(161)
Depreciation and amortization	7,402	7,768
Impairment loss	543	—
Financial income	(118)	(66)
Financial expenses	612	644
Gain (loss) on sales of shares of subsidiaries and affiliates	(14,622)	161
Profit (loss) on sale and disposal of property, plant and equipment and intangible assets	(632)	93
Increase (decrease) in trade and other receivables	(501)	917
Increase in inventories	(11,793)	(5,311)
Increase (decrease) in trade and other payables	1,474	(1,598)
Increase (decrease) in refund liabilities	(814)	637
Increase (decrease) in provisions	32	(12,799)
Increase in other financial liabilities	267	361
Other	(4,021)	1,246
Subtotal	3,861	(147)
Interest received	1	1
Dividends received	116	45
Interest paid	(326)	(483)
Income taxes paid	(859)	(1,267)
Income taxes refund	4,207	23
Cash flows generated from (used in) operating activities	7,000	(1,828)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(15,685)	(7,734)
Sale of property, plant and equipment	782	7
Acquisition of intangible assets	(3,448)	(7,244)
Expenditure for purchases of investment securities	(1,581)	—
Proceeds from the sale of investment securities	6,443	107
Purchase of subsidiary shares and others resulting in change in the scope of consolidation	—	(301)
Proceeds from the sale of subsidiary shares involving a change in the scope of consolidation	28,429	1,451
Other	(30)	(57)
Cash flows generated from (used in) investing activities	14,910	(13,771)
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	(5,832)	16,325
Proceeds from long-term borrowings	35,036	—
Repayments of long-term borrowings	(28,685)	(2,173)
Proceeds from the issuance of bonds	9,941	—
Payments of lease liabilities	(844)	(867)
Purchase of treasury shares	(16,068)	—
Dividends paid	(2,847)	(3,117)
Others	(6)	(13)
Cash flows generated from (used in) financing activities	(9,305)	10,155
Effect of exchange rate change on cash and cash equivalents	(375)	25
Net increase (decrease) in cash and cash equivalents	12,231	(5,418)
Cash and cash equivalents at beginning of the period	26,368	38,785
Increase in cash and cash equivalents included in assets held for sale	11,061	—
Cash and cash equivalents at end of the period	49,660	33,367

(5) Selected Notes to Condensed Interim Consolidated Financial Statements

(Significant Uncertainty Regarding Going Concern Assumption)

Not applicable

(Discontinued Operation)

The Company has recorded profit/loss related to the U.S. Business under the category of “discontinued operation.”

(1) Discontinued Operation

	Millions of yen	
	Six months ended September 30, 2024	Six months ended September 30, 2025
Discontinued Operation		
Revenue *1	14,622	—
Expenses *1	—	(161)
Profit before tax on the discontinued operation	14,622	(161)
Income tax expenses*2	(3,592)	(1)
Profit for the period on the discontinued operation	11,029	(162)

Profit on the discontinued operation attributable to:

Owners of parent	11,029	(162)
------------------	--------	-------

*1 Revenue includes a gain of JPY 14,622 million on the transfer of the Company’s shares and interests in the U.S. subsidiary and affiliates, which has been recorded for the six months ended September 30, 2024, and expenses include a loss of JPY 161 million on the transfer of the Company’s shares and interests in the U.S. subsidiary and affiliates, which has been recorded for the six months ended September 30, 2025.

*2 Income tax expenses include tax expense related to gain on the transfer of the Company’s shares and interests in the U.S. subsidiary and affiliates of JPY 3,592 million in the Six months ended March 31, 2025 and JPY 1 million in the Six months ended March 31, 2026 respectively.

(2) Cash flows from discontinued operation

	Millions of yen	
	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from operating activities	—	—
Cash flows from investing activities *	28,429	1,451
Cash flows from financing activities	—	—
Total	28,429	1,451

* On April 2, 2024, the procedure of transferring all corresponding shares was completed. The following table shows the relationship between income and expenditure from the share transfer.

	Millions of yen	
	Six months ended September 30, 2024	Six months ended September 30, 2025
Consideration for the transfer *	39,490	1,451
Cash and cash equivalents of assets at the time of loss of control	(11,061)	—
Proceeds from the transfer of shares in the consolidated subsidiary involving changes in the scope of consolidation	28,429	1,451

* As for the consideration for the transfer, the final amount may change since the price adjustment clause and contingent consideration, are stipulated in the Share Transfer Agreement. As the consideration for the transfer, the Company received JPY 24,180 million from Bora for the trading value of the Company's interest and received JPY 15,310 million from the purchase of treasury shares of SAH during the six months ended September 30, 2024.

(Segment Information)

The operating segments of Sawai are the components for which separate financial information is available, and the Board of Directors, regularly examines the financial information in deciding how to allocate management resources, assessing the Group's past performance and forecasting its future performance.

The segment for the manufacturing and sale of pharmaceutical and other products mainly consist of five consolidated subsidiaries: Sawai Pharmaceutical, Kaken Shoyaku Co., Ltd. and Trust Pharmatech, which manufacture and sell generic pharmaceutical products, Medisa Shinyaku Inc., which sells generic pharmaceutical products, and FrontAct, which mainly manufactures and sells medical devices.

The following table shows revenue for our key therapeutic category:

	Millions of yen	
Products	Six months ended September 30, 2024	Six months ended September 30, 2025
Cardiovascular drugs	20,415	22,946
Central nervous system drugs	12,213	13,944
Other metabolic drugs	9,578	11,536
Gastro-intestinal drugs	9,879	11,216
Blood/body fluid pharmaceutical products	7,958	10,154
Antibiotics drugs	5,760	5,118
Antiallergic drugs	3,321	3,930
Drugs for respiratory organs	3,638	3,790
Vitamin preparations	3,498	3,614
Antineoplastic agents	3,205	3,220
Drugs for urogenital organs and the anus	2,462	2,700
Other	5,943	6,676
Total	87,870	98,843

(Events after Reporting Period)**(1) Issuance of Unsecured Bonds**

At a meeting held on October 24, 2025, the Board of Directors approved a comprehensive resolution with the following provisions regarding the issuance of domestic unsecured straight bonds.

1. Total amount of bonds that can be issued multiple times: Up to JPY 8,000 million
2. Scheduled period of issuance: From November 1, 2025 to March 31, 2026
3. Amount to be paid: 100 yen per bond with a face value of 100 yen
4. Maximum interest rate: Yield on JGBs with roughly the same remaining maturity as the redemption period + 1.00%
5. Redemption period: Within 10 years
6. Redemption method: Lump-sum redemption at maturity
7. Planned uses of funds: Capital investment, working capital, and repayment of borrowings through loans provided to subsidiaries